BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12368157)

  • 1. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
    Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G
    Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.
    Murgue B; Tsunekawa S; Rosenberg I; deBeaumont M; Podolsky DK
    Cancer Res; 1994 Oct; 54(19):5206-11. PubMed ID: 7923141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer.
    Jang JH; Shin KH; Park YJ; Lee RJ; McKeehan WL; Park JG
    Cancer Res; 2000 Aug; 60(15):4049-52. PubMed ID: 10945607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
    Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
    Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
    Cornish EE; Natoli RC; Hendrickson A; Provis JM
    Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
    Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
    Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14).
    Intini D; Baldini L; Lombardi L; Neri A
    Leukemia; 2002 Jun; 16(6):1201-2. PubMed ID: 12040455
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
    Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
    Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular study of the t(4;14) in multiple myeloma.
    Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
    Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
    Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
    Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
    Intini D; Baldini L; Fabris S; Lombardi L; Ciceri G; Maiolo AT; Neri A
    Br J Haematol; 2001 Aug; 114(2):362-4. PubMed ID: 11529856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.
    Yagasaki F; Wakao D; Yokoyama Y; Uchida Y; Murohashi I; Kayano H; Taniwaki M; Matsuda A; Bessho M
    Cancer Res; 2001 Dec; 61(23):8371-4. PubMed ID: 11731410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
    Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
    Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells.
    Jang JH
    Biochem Biophys Res Commun; 2002 Mar; 292(2):378-82. PubMed ID: 11906172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
    Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
    Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
    Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
    Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
    Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.